SMARCA1 and cancer: On the other hand, the sensitivity of ARID1A-deficient cancer cell lines to CBP/p300 dual inhibitors was intermediate between SWI/SNF WTs and the sensitive genotypes (SMARCA4/SMARCA2-deficient and SS18–SSX fusion).